Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Opus Genetics, Inc.NASDAQ: IRD
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $5.93M fell 6.5% year over year, behind the +8.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 21.3% from the prior quarter. Over 3 fiscal years it compounded at +44.6% a year.
Context
- Selling, general & admin amounted to 154.9% of revenue in FY2025, down 10.9 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 13 analysts of $47.42M (+115.7%) for the fiscal year ending Dec 2026, a step up from the +20.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.93M+21.3% QoQ
- Last fiscal yearDec 2025
- $21.98M+20.7% YoY
- LTMMar 2026
- $21.57M+8.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 21.98M USD
- Year-over-year change
- +20.7%
- 4-year CAGR
- +28.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.98M | +20.7% |
| FY2024 | 2024-12-31 | 18.22M | +52.3% |
| FY2023 | 2023-12-31 | 11.96M | +64.5% |
| FY2022 | 2022-12-31 | 7.27M | -10.5% |
| FY2021 | 2021-12-31 | 8.12M | — |
Selling, General & Admin vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 selling, general & admin of $21.57M is the 7th highest of the 10 companies compared; the peer median is $35.34M.
- Its year-over-year change of +8.6% is the 2nd highest of 10, against a peer median of -24.5%.
- Selling, general & admin amounts to 180.0% of revenue for IRD, versus a peer median of 263.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46B | +48531.9% | -28.7% | — | |
| LTM Mar 2026 | $47.37M | -20.9% | -4.0% | 257.2% | |
| LTM Mar 2026 | $45.53M | -35.6% | -12.4% | 36.8% | |
| LTM Mar 2026 | $40.57M | -24.5% | -6.8% | 269.8% | |
| LTM Mar 2026 | $35.34M | -27.5% | -17.7% | 3080.9% | |
| LTM Mar 2026 | $23.46M | -41.6% | -24.1% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $21.57M | +8.6% | +44.6% | 180.0% |
| LTM Mar 2026 | $18.46M | -7.7% | +13.7% | — | |
| LTM Mar 2026 | $10.32M | -12.0% | -7.1% | — | |
| LTM Mar 2026 | $3.55M | -47.4% | +11.8% | — | |
| Peer median (excluding IRD) | $35.34M | -24.5% | -7.1% | 263.5% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 15.17M | 14.36M | 17.65M | 26.85M | 30.81M |
| Selling, General & Admin | 8.12M | 7.27M | 11.96M | 18.22M | 21.98M |
| Operating Expenses | 23.29M | 21.62M | 29.61M | 73.07M | 52.8M |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| EBITDA | (56.69M) | 18.22M | (9.97M) | (57.52M) | (48.07M) |
| EBITDA Margin | -9624.3% | 45.7% | -52.3% | -523.3% | -338.6% |
| Operating Income | (22.71M) | 18.23M | (10.56M) | (62.07M) | (38.6M) |
| Operating Margin | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2K | 9K | 1.33M | 0 | 1.47M |
| Other Income / Expenses | (33.99M) | (23K) | 589K | 4.54M | (10.99M) |
| Income Before Tax | (56.69M) | 18.2M | (9.97M) | (57.53M) | (49.59M) |
| Pre-Tax Margin | -9625.3% | 45.7% | -52.4% | -523.4% | -349.3% |
| Income Tax Expense | 0 | 315K | 12K | 0 | 0 |
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Net Margin | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (Basic) | (3.82) | 0.90 | (0.46) | (2.15) | (0.80) |
| EPS (Diluted) | (3.82) | 0.87 | (0.46) | (2.15) | (0.80) |
| Weighted Avg Shares | 14.85M | 19.93M | 21.59M | 26.72M | 622.22M |
| Weighted Avg Shares (Diluted) | 14.85M | 20.6M | 21.59M | 26.72M | 622.22M |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.